Literature DB >> 15067524

Structure-activity relationships in platinum-acridinylthiourea conjugates: effect of the thiourea nonleaving group on drug stability, nucleobase affinity, and in vitro cytotoxicity.

Margaret C Ackley1, Colin G Barry, Amanda M Mounce, Michael C Farmer, Beth-Erin Springer, Cynthia S Day, Marcus W Wright, Susan J Berners-Price, Suzanne M Hess, Ulrich Bierbach.   

Abstract

The synthesis, cytotoxicity, and nucleoside binding of some platinum-acridinylthiourea conjugates derived from the prototypical compound [PtCl(en)(ACRAMTU)](NO3)2 ("PT-ACRAMTU"; en=ethane-1,2-diamine, ACRAMTU=1-[2-(acridin-9-ylamino)ethyl]-1,3-dimethylthiourea, protonated form) are reported. To establish structure-activity relationships within this class of compounds, systematic changes were made to the thiourea nonleaving group, which links the intercalator to platinum. Three new derivatives of ACRAMTU, one di-, one tri-, and one tetraalkylated, were generated, where the degree of alkylation indicates the number of alkyl groups attached to the SCN2 framework. Subsequent reaction of the tri- and tetraalkylated derivatives with activated [PtCl2(en)] yielded the corresponding platinum conjugates. The dialkylated thiourea gave an unstable complex, which was not included in the studies. The crystal structure of PT-ACRAMTU x MeOH has been determined. In the solid state, one axial position of the square-planar platinum coordination sphere is partially shielded by the bulky thiourea group, providing a strong rationale for the kinetic inertness of the compound. The cytotoxicity of the prototype, the two new conjugates, and cisplatin was assessed in ovarian (A2780, A2780/CP), lung (NCI-H460), and colon (RKO) cancer cell lines using clonogenic survival assays. The derivatives containing trialkylated thiourea groups showed activity similar or superior to cisplatin, with IC50 values in the low micromolar concentration range. The complex modified with the tetraalkylated (bulkiest) thiourea was significantly less active, possibly due to the greatly decreased rate of binding to nucleobase nitrogen (1H NMR spectroscopy), but was most efficient at overcoming cross resistance to cisplatin in A2780/CP. Possible consequences of the reported structural modifications for the mechanism of action of these agents are discussed. Copyright 2004 SBIC

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15067524     DOI: 10.1007/s00775-004-0541-4

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  8 in total

1.  Structure, Recognition, and Processing of Cisplatin-DNA Adducts.

Authors:  E R Jamieson; S J Lippard
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

2.  In vitro studies on the mechanisms of oxaliplatin resistance.

Authors:  S Hector; W Bolanowska-Higdon; J Zdanowicz; S Hitt; L Pendyala
Journal:  Cancer Chemother Pharmacol       Date:  2001-11       Impact factor: 3.333

3.  Unusual intercalation of acridin-9-ylthiourea into the 5'-GA/TC DNA base step from the minor groove: implications for the covalent DNA adduct profile of a novel platinum-intercalator conjugate.

Authors:  Hemanta Baruah; Ulrich Bierbach
Journal:  Nucleic Acids Res       Date:  2003-07-15       Impact factor: 16.971

4.  Thermally inert metal ammines as light-inducible DNA-targeted agents. Synthesis, photochemistry, and photobiology of a prototypical rhodium(III)-intercalator conjugate.

Authors:  Colin G Barry; Elizabeth C Turney; Cynthia S Day; Gilda Saluta; Gregory L Kucera; Ulrich Bierbach
Journal:  Inorg Chem       Date:  2002-12-30       Impact factor: 5.165

5.  Design, synthesis, and biological activity of a novel non-cisplatin-type platinum-acridine pharmacophore.

Authors:  E T Martins; H Baruah; J Kramarczyk; G Saluta; C S Day; G L Kucera; U Bierbach
Journal:  J Med Chem       Date:  2001-12-06       Impact factor: 7.446

6.  Antitumor activity of 13,14-dihydro-15-deoxy-delta7-prostaglandin-A1-methyl ester integrated into lipid microspheres against human ovarian carcinoma cells resistant to cisplatin in vivo.

Authors:  H Sasaki; S Niimi; M Akiyama; T Tanaka; A Hazato; S Kurozumi; S Fukushima; M Fukushima
Journal:  Cancer Res       Date:  1999-08-15       Impact factor: 12.701

7.  Mechanism of action of non-cisplatin type DNA-targeted platinum anticancer agents: DNA interactions of novel acridinylthioureas and their platinum conjugates.

Authors:  Hemanta Baruah; Christopher L Rector; Susanne M Monnier; Ulrich Bierbach
Journal:  Biochem Pharmacol       Date:  2002-07-15       Impact factor: 5.858

8.  Unprecedented monofunctional metalation of adenine nucleobase in guanine- and thymine-containing dinucleotide sequences by a cytotoxic platinum-acridine hybrid agent.

Authors:  Colin G Barry; Hemanta Baruah; Ulrich Bierbach
Journal:  J Am Chem Soc       Date:  2003-08-13       Impact factor: 15.419

  8 in total
  16 in total

Review 1.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

2.  Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair.

Authors:  Hana Kostrhunova; Jaroslav Malina; Amanda J Pickard; Jana Stepankova; Marie Vojtiskova; Jana Kasparkova; Tereza Muchova; Matthew L Rohlfing; Ulrich Bierbach; Viktor Brabec
Journal:  Mol Pharm       Date:  2011-08-17       Impact factor: 4.939

3.  Human Serum Albumin-Delivered [Au(PEt3)]+ Is a Potent Inhibitor of T Cell Proliferation.

Authors:  Tyler C Dean; Mu Yang; Mingyong Liu; Jason M Grayson; Anthony W DeMartino; Cynthia S Day; Jingyun Lee; Cristina M Furdui; Ulrich Bierbach
Journal:  ACS Med Chem Lett       Date:  2017-04-25       Impact factor: 4.345

4.  Probing platinum-adenine-n3 adduct formation with DNA minor-groove binding agents.

Authors:  Lu Rao; Tiffany K West; Gilda Saluta; Gregory L Kucera; Ulrich Bierbach
Journal:  Chem Res Toxicol       Date:  2010-07-19       Impact factor: 3.739

5.  Unusual Reactivity of a Potent Platinum-Acridine Hybrid Antitumor Agent.

Authors:  Leigh A Graham; Gary M Wilson; Tiffany K West; Cynthia S Day; Gregory L Kucera; Ulrich Bierbach
Journal:  ACS Med Chem Lett       Date:  2011-09-08       Impact factor: 4.345

Review 6.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

7.  Rates of intercalator-driven platination of DNA determined by a restriction enzyme cleavage inhibition assay.

Authors:  Jayati Roy Choudhury; Lu Rao; Ulrich Bierbach
Journal:  J Biol Inorg Chem       Date:  2010-11-18       Impact factor: 3.358

8.  Replacement of a thiourea-S with an amidine-NH donor group in a platinum-acridine antitumor compound reduces the metal's reactivity with cysteine sulfur.

Authors:  Zhidong Ma; Lu Rao; Ulrich Bierbach
Journal:  J Med Chem       Date:  2009-05-28       Impact factor: 7.446

9.  Synthesis and biological evaluation of platinum-acridine hybrid agents modified with bipyridine non-leaving groups.

Authors:  Alexander R Kheradi; Gilda Saluta; Gregory L Kucera; Cynthia S Day; Ulrich Bierbach
Journal:  Bioorg Med Chem Lett       Date:  2009-05-18       Impact factor: 2.823

10.  Effect of linkage geometry on biological activity in thiourea- and guanidine-substituted acridines and platinum-acridines.

Authors:  Zhidong Ma; Gilda Saluta; Gregory L Kucera; Ulrich Bierbach
Journal:  Bioorg Med Chem Lett       Date:  2008-05-16       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.